Personalized cancer treatments powered by diagnostic insights 

At Welmedis, we are dedicated to transforming cancer care through the development of personalized therapeutics. By leveraging genomic data from the RGCC diagnostic platform, we identify novel targets for small-molecule drugs specifically tailored to distinct patient populations. Our innovative approach seamlessly integrates cutting-edge diagnostics with drug development, ensuring the most effective treatments for specific cancer types. 

Located in Wädenswil, Switzerland, we operate state-of-the-art laboratories that drive pre-clinical development. Through advanced computational chemistry, automated synthesis, and modern medicinal chemistry techniques, we accelerate the development of next-generation therapies. 

This effort is strongly supported by the Molecular Biology, Cell Biology and Protein Chemistry laboratory, operated by RGCC Central Europe, our Molecular Biology and Medicine laboratory, operated by RGCC Greece, along with collaborative partnerships with CROs, all working together to achieve success in drug discovery.